Trial Profile
A Phase III, 52 Week, Randomized, Double-blind, 3-arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI With the Fixed Dose Dual Combinations of FF/VI and UMEC/VI, All Administered Once-daily in the Morning Via a Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Nov 2023
Price :
$35
*
At a glance
- Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary) ; Umeclidinium/vilanterol; Vilanterol/fluticasone furoate
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms IMPACT
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 13 Sep 2023 Results of post hoc analysis assessing risk of death, hospitalization, CVAESI, or exacerbation by CIIS and P pulmonale (yes vs no), and by treatment, presented at the 33rd Annual Congress of the European Respiratory Society
- 24 May 2023 Results assessing the annual exacerbation rate as outcome and used machine learning (ML) models to predict individual treatment effects from subjects from the fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI, n=4134) and UMEC/VI (n=2070) arms in the IMPACT trial, presented at the 119th International Conference of the American Thoracic Society.
- 24 May 2023 Post-hoc analysis results presented at the 119th International Conference of the American Thoracic Society.